Foundation

European Medicines Agency

The European Medicines Agency (EMA) has established ‘eligibility criteria’ in order to make sure that it only establishes dialogue with the most suitable organisations that act in the interests of European patients, consumers and healthcare professionals. The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) would like to engage in dialogue with the EMA and has provided the following information for the evaluation of eligibility.

As part of the evaluation for eligibility, ECTRIMS has provided the following financial information to be assessed by the parameters as set by the European Medicines Agency:

Funding Sources:

The following pharmaceutical companies provide funding to ECTRIMS:

  • 4S DAWN Clinical Software, United Kingdom
  • Aequus Research, United Kingdom
  • Alexion Pharmaceuticals, USA
  • Almirall SA, Spain
  • BARTS-MS, United Kingdom
  • Bayer AG, Germany
  • Biogen, Switzerland
  • Biosidus S.A., Argentina
  • Celgene Corporation, USA
  • CorTechs Labs, USA
  • Digesting Science, United Kingdom
  • EDMUS, France
  • Elsevier, The Netherlands
  • Excemed, Italy
  • Hoffmann-La Roche Ltd, Switzerland
  • Forward Pharma A/S, Denmark
  • Heidelberg Engineering GmbH, Germany
  • Icometrix, Belgium
  • IXICO plc, United Kingdom
  • jung diagnostics GmbH, Germany
  • Mallinckrodt Pharmaceuticals, USA
  • Medday Pharmaceuticals, France
  • Merck, Germany
  • Mint Labs, Spain
  • NARCOMS & CMSC, USA
  • Neuro-Compass, United Kingdom
  • Novartis Pharma AG, Switzerland
  • PPD, USA
  • Renovo Neural, Inc., USA
  • Sage Publishing, United Kingdom
  • Sanofi Genzyme, The Netherlands
  • Shift.ms, United Kingdom
  • Teva Pharmaceuticals Europe, The Netherlands
  • Teva Pharmaceuticals, USA

The highest contribution from a single company is less than 6.57% of the organisation’s total income.

Code of Conduct:

ECTRIMS operates within the established code of conduct or the European Medicines Agency.

[fMRI during simple motor task; healthy volunteer (top) and PP MS subject (bottom) Photo M. Filippi, Ospedale San Raffaele, Milan
Pathology of SPMS Photo H. Lassmann, University of Vienna
MS t-cells Photo H. Lassmann, University of Vienna
Arcuate fasciculus impacted by MS lesion Photo M. Filippi, Ospedale San Rafaelle, Milan
Photo Congrex
optic disc palor after acute ON. Courtesy A. Toosy, London